RMEBX
Price
$64.44
Change
+$0.03 (+0.05%)
Updated
Jul 31 closing price
Net Assets
118.05B
WEECX
Price
$10.90
Change
+$0.04 (+0.37%)
Updated
Jul 31 closing price
Net Assets
38.91M
Interact to see
Advertisement

RMEBX vs WEECX

RMEBX vs WEECX Comparison Chart in %
View a ticker or compare two or three
VS
RMEBX vs. WEECX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMEBX is a Buy and WEECX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 118B vs. WEECX (38.9M). RMEBX pays higher dividends than WEECX: RMEBX (0.99) vs WEECX (0.00). RMEBX was incepted earlier than WEECX: RMEBX (12 years) vs WEECX (33 years). WEECX (1.68) is less costly to investors than RMEBX (1.07). WEECX is a more actively managed with annual turnover of: 75.00 vs. RMEBX (30.00). RMEBX has a lower initial minimum investment than WEECX: RMEBX (250) vs WEECX (1000). RMEBX annual gain was more profitable for investors over the last year : 8.96 vs. WEECX (-4.22). RMEBX return over 5 years is better than : 36.13 vs. WEECX (-18.68).
RMEBXWEECXRMEBX / WEECX
Total Expense Ratio1.071.6864%
Annual Report Gross Expense Ratio1.071.6864%
Fund Existence12 years33 years-
Gain YTD9.4168.458111%
Front LoadN/A4%-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets118B38.9M303,342%
Annual Yield % from dividends0.990.00-
Returns for 1 year8.96-4.22-212%
Returns for 3 years32.63-1.90-1,717%
Returns for 5 years36.13-18.68-193%
Returns for 10 years90.64-10.71-847%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOTX15.100.17
+1.14%
Voya Large Cap Growth Port S2
JRAAX88.86N/A
N/A
Janus Henderson Research A
VLLIX45.39-0.03
-0.07%
Value Line Larger Companies Focus Instl
BHCFX21.68-0.10
-0.46%
Baron Health Care Retail
FBDIX193.96-3.99
-2.02%
Franklin Biotechnology Discovery A